Paolo Tarantino: In a large RW cohort we found that nearly 30% of breast tumors changed HER2 status after neoadjuvant treatment

Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:

“In a large (≃1000) RW cohort from Dana Farber, consistently with prior reports, we found that nearly 30% of breast tumors changed HER2 status after neoadjuvant treatment. This only impacted prognosis if HER2+HER2-neg. Our latest article now out on EJC.”

Source: Paolo Tarantino/X